{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:54:09Z","timestamp":1788976449021,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T00:00:00Z","timestamp":1423958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,4]]},"abstract":"\n Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present\n post hoc<\/jats:italic>\n analysis of pooled data from four placebo\u2010controlled phase\n III<\/jats:styled-content>\n studies assessed the effect of canagliflozin, a sodium\u2010glucose co\u2010transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (\n T2DM<\/jats:styled-content>\n ) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid \u2265475\u2009\u00b5mol\/l (\u223c8\u2009mg\/dl)]. At week\u200926, canagliflozin 100 and 300\u2009mg were associated with a \u223c13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo\u2010subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of <360\u2009\u00b5mol\/l (\u223c6\u2009mg\/dl) with both canagliflozin 100\u2009mg (23.5%) and 300\u2009mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with\n T2DM<\/jats:styled-content>\n , including those with baseline hyperuricaemia.\n <\/jats:p>","DOI":"10.1111\/dom.12439","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T04:09:53Z","timestamp":1421726993000},"page":"426-429","source":"Crossref","is-referenced-by-count":118,"title":["Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus"],"prefix":"10.1111","volume":"17","author":[{"given":"M. J.","family":"Davies","sequence":"first","affiliation":[{"name":"Janssen Scientific Affairs LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trujillo","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vijapurkar","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. V.","family":"Damaraju","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Meininger","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2753"},{"key":"e_1_2_7_5_1","first-page":"1655","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Becker M","year":"1995"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027817"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078206"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S5476"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12322"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050197"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:58Z","timestamp":1761886678000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/dom.12439"],"URL":"https:\/\/doi.org\/10.1111\/dom.12439","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}